Jen Fitzpatrick was Appointed as Vice President and Corporate Counsel at Sage-Therapeutics

Date of management change: September 06, 2018 

What Happened?

Cambridge, -based Sage-Therapeutics Appointed Jen Fitzpatrick as Vice President and Corporate Counsel


About the Company

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.


About the Person

Jen Fitzpatrick is Vice President and Corporate Counsel at Sage Therapeutics. Previously, Jen held various senior legal leadership roles in the industry.


Info Source



Other IT executives who recently changed jobs as well: Mendenhall Bill, Castle Scott, Parks Reggie, Cetron Brad, Ferrell Raymond, Wamsley Douglas, Kaplan Robert, Langlais Catherine, Oroschakoff Michelle, Tubb Allen, Hallee Jesse

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.